

L Number	Hits	Search Text	DB	Time stamp
1	258	quinazolinone with amino	USPAT; US-PGPUB	2003/10/24 17:06

EAST

10/089, 166

10/ 089,166

Welcome to STN International! Enter x:x

LOGINID:sssptal202txn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 SEP 09 CA/Capplus records now contain indexing from 1907 to the  
present  
NEWS 4 AUG 05 New pricing for EUROPATFULL and PCTFULL effective  
August 1, 2003  
NEWS 5 AUG 13 Field Availability (/FA) field enhanced in BEILSTEIN  
NEWS 6 AUG 18 Data available for download as a PDF in RDISCLOSURE  
NEWS 7 AUG 18 Simultaneous left and right truncation added to PASCAL  
NEWS 8 AUG 18 FROSTI and KOSMET enhanced with Simultaneous Left and Right  
Truncation  
NEWS 9 AUG 18 Simultaneous left and right truncation added to ANABSTR  
NEWS 10 SEP 22 DIPPR file reloaded  
NEWS 11 SEP 25 INPADOC: Legal Status data to be reloaded  
NEWS 12 SEP 29 DISSABS now available on STN  
NEWS 13 OCT 10 PCTFULL: Two new display fields added  
NEWS 14 OCT 21 BIOSIS file reloaded and enhanced  
  
NEWS EXPRESS OCTOBER 01 CURRENT WINDOWS VERSION IS V6.01a, CURRENT  
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),  
AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 17:54:05 ON 22 OCT 2003

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 17:54:37 ON 22 OCT 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

10/ 089,166

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 OCT 2003 HIGHEST RN 607679-40-3  
DICTIONARY FILE UPDATES: 21 OCT 2003 HIGHEST RN 607679-40-3

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.


Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>  
Uploading 10089166.str

L1 STRUCTURE UPLOADED

=> d l1  
L1 HAS NO ANSWERS  
L1 STR

Ak



Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful  
FULL SEARCH INITIATED 17:55:08 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 313260 TO ITERATE

100.0% PROCESSED 313260 ITERATIONS 29 ANSWERS  
SEARCH TIME: 00.00.14

L2 29 SEA SSS FUL L1

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	148.15	148.36

FILE 'CAPLUS' ENTERED AT 17:55:28 ON 22 OCT 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

10/ 089,166

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Oct 2003 VOL 139 ISS 17  
FILE LAST UPDATED: 21 Oct 2003 (20031021/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2

L3 3 L2

=> d l3 1- ibib abs hitstr

YOU HAVE REQUESTED DATA FROM 3 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN



ACCESSION NUMBER: 2001:247321 CAPLUS  
DOCUMENT NUMBER: 134:280852  
TITLE: Quinazolinones useful as glycoprotein I $\beta$ IX antagonists, and their preparation and use for control of thrombotic disorders  
INVENTOR(S): Mederski, Werner; Devant, Ralf; Barnickel, Gerhard; Bernotat-danielowski, Sabine; Melzer, Guido; Dhanoa, Daljit; Zhao, Bao-ping; Rinker, James; Player, Mark; Soll, Richard  
PATENT ASSIGNEE(S): Merck Patent Gmbh, Germany; et al.  
SOURCE: PCT Int. Appl., 104 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

*Applicant's  
PCT*

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001023365	A1	20010405	WO 2000-EP8940	20000913
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
BR 2000014294	A	20020521	BR 2000-14294	20000913
EP 1216235	A1	20020626	EP 2000-965991	20000913
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
NO 2002001502	A	20020326	NO 2002-1502	20020326
PRIORITY APPLN. INFO.:			US 1999-407958	A 19990928

OTHER SOURCE(S):  
GI

MARPAT 134:280852



AB Quinazolinones I and their pharmaceutically tolerable salts and solvates are disclosed [in which R, R<sub>1</sub> = H, A, OH, OA, OCH<sub>2</sub>Ar, Hal, NH<sub>2</sub>, NHA, NA<sub>2</sub>, NO<sub>2</sub>, cyano, COR<sub>2</sub>, CONH<sub>2</sub>, CONHA, CONA<sub>2</sub>, CO<sub>2</sub>H, CO<sub>2</sub>A, SO<sub>2</sub>A; R<sub>2</sub>, R<sub>3</sub> = H, A, C(:NH)NH<sub>2</sub>, solid phase; R<sub>4</sub> = Ar, phenylalkyl, cycloalkyl, Het; Y = bond, C<sub>2</sub>-4 alkylene; Z = bond, phenylene; A = (un)branched C<sub>1</sub>-6 alkyl; Ar = (un)substituted Ph, naphthyl, biphenyl, or benzofuranyl; Het = (un)substituted, (un)satd. mono- or bicyclic NOS heterocyclyl; Hal = F, Cl, Br, or iodo; n = 1-3; m = 0-3; with a variety of provisos]. The compds. are glycoprotein IbIX antagonists (no data), useful for treatment or prophylaxis of a variety of thrombotic disorders, or as anti-adhesive substances for implants, catheters, or heart pacemakers. For instance, an exemplary amine, 3-(aminomethyl)benzylamine, was supported on p-nitrophenyl carbonate resin, then coupled with various Fmoc-protected anthranilic acids. Cleavage of the Fmoc group, cyclocondensation with various aldehydes R<sub>4</sub>YCHO, oxidn. of the resultant dihydroquinazolinone ring system, and cleavage from the resin with CF<sub>3</sub>CO<sub>2</sub>H, gave a variety of compds. I, e.g., the preferred compd. II.

IT **332361-72-5P**, 3-(3-Aminopropyl)-6-chloro-2-(2-furan-2-ylvinyl)-3H-quinazolin-4-one **332361-73-6P**, 3-(3-Aminopropyl)-6-methyl-2-(2-furan-2-ylvinyl)-3H-quinazolin-4-one **332361-74-7P**, 3-(3-Aminopropyl)-7-chloro-2-(2-furan-2-ylvinyl)-3H-quinazolin-4-one **332361-75-8P**, 3-(3-Aminopropyl)-6-methoxy-2-(2-furan-2-ylvinyl)-3H-quinazolin-4-one **332361-76-9P**, 3-(3-Aminopropyl)-2-(2-furan-2-ylvinyl)-3H-quinazolin-4-one **332362-12-6P**, 3-(3-Aminopropyl)-2-styryl-6-chloro-3H-quinazolin-4-one **332362-13-7P**, 3-(3-Aminopropyl)-2-styryl-6-methyl-3H-quinazolin-4-one **332362-14-8P**, 3-(3-Aminopropyl)-2-styryl-7-chloro-3H-quinazolin-4-one **332362-15-9P**, 3-(3-Aminopropyl)-2-styryl-6-methoxy-3H-quinazolin-4-one **332362-16-0P**, 3-(3-Aminopropyl)-2-styryl-3H-quinazolin-4-one


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

10/ 089,166

(drug candidate)


RN 332361-72-5 CAPLUS

CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-6-chloro-2-[2-(2-furanyl)ethenyl]-  
(9CI) (CA INDEX NAME)




RN 332361-73-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-2-[2-(2-furanyl)ethenyl]-6-methyl-  
(9CI) (CA INDEX NAME)




RN 332361-74-7 CAPLUS

CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-7-chloro-2-[2-(2-furanyl)ethenyl]-  
(9CI) (CA INDEX NAME)




RN 332361-75-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-2-[2-(2-furanyl)ethenyl]-6-methoxy-  
(9CI) (CA INDEX NAME)




RN 332361-76-9 CAPLUS


CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-2-[2-(2-furanyl)ethenyl]- (9CI)  
(CA INDEX NAME)




RN 332362-12-6 CAPLUS  
 CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-6-chloro-2-(2-phenylethenyl)- (9CI)  
 (CA INDEX NAME)




RN 332362-13-7 CAPLUS  
 CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-6-methyl-2-(2-phenylethenyl)- (9CI)  
 (CA INDEX NAME)



RN 332362-14-8 CAPLUS  
 CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-7-chloro-2-(2-phenylethenyl)- (9CI)  
 (CA INDEX NAME)




RN 332362-15-9 CAPLUS  
 CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-6-methoxy-2-(2-phenylethenyl)- (9CI)  
 (CA INDEX NAME)




RN 332362-16-0 CAPLUS  
 CN 4(3H)-Quinazolinone, 3-(3-aminopropyl)-2-(2-phenylethenyl)- (9CI) (CA

INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN  
 ACCESSION NUMBER: 2000:248569 CAPLUS  
 DOCUMENT NUMBER: 133:17770  
 TITLE: Solid phase synthesis of styrylquinazolinones  
 AUTHOR(S): Theoclitou, Maria-Elena; Ostresh, John M.; Hamashin, Vince; Houghten, Richard A.  
 CORPORATE SOURCE: Torrey Pines Institute for Molecular Studies, San Diego, CA, 92121, USA  
 SOURCE: Tetrahedron Letters (2000), 41(13), 2051-2054  
 CODEN: TELEAY; ISSN: 0040-4039.  
 PUBLISHER: Elsevier Science Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 133:17770  
 GI



I

AB The solid phase synthesis of styrylquinazolinones I (R = 4-HOC6H4CH2, H, Me; R1 = H, Me, Et; R2 = H, Br, Me, NO2; R3 = Ph, 2-MeOC6H4, 4-Et2NC6H4, 2-FC6H4, 6-methyl-2-pyridinyl, 3-pyridinyl, 4-BrC6H4, 3-F3CC6H4, 2,3-F2C6H3, 3-PhOC6H4) is described. Starting from resin-bound amino acids, and employing alkylation, acylation with anthranilic acids, acetylation/cyclocondensation, and aryl aldehyde condensation reactions, the desired styrylquinazolinones were prepd. in good yield and high purity.

IT 273205-37-1P 273205-38-2P 273205-39-3P  
 273205-40-6P 273205-41-7P 273205-42-8P  
 273205-43-9P 273205-44-0P 273205-45-1P  
 273205-46-2P 273205-47-3P 273205-48-4P  
 273205-49-5P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (solid-phase synthesis of styrylquinazolinones from resin-bound amino acids via alkylation, anthranilic acid acylation, acetylation/cyclocondensation, and aryl aldehyde condensation reactions)

RN 273205-37-1 CAPLUS


CN 3(4H)-Quinazolineacetamide, .alpha.-[(4-hydroxyphenyl)methyl]-4-oxo-2-(2-




10/ 089,166

phenylethenyl)-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 273205-38-2 CAPLUS  
CN 3(4H)-Quinazolineacetamide, 2-[2-(2-methoxyphenyl)ethenyl]-N-methyl-4-oxo-  
(9CI) (CA INDEX NAME)




RN 273205-39-3 CAPLUS  
CN 3(4H)-Quinazolineacetamide, 2-[2-[4-(diethylamino)phenyl]ethenyl]-4-oxo-  
(9CI) (CA INDEX NAME)




RN 273205-40-6 CAPLUS  
CN 3(4H)-Quinazolineacetamide, 2-[2-(2-fluorophenyl)ethenyl]-.alpha.-methyl-4-oxo-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.

10/ 089,166




RN 273205-41-7 CAPLUS  
CN 3(4H)-Quinazolineacetamide, 8-bromo-N-methyl-4-oxo-2-(2-phenylethenyl)-  
(9CI) (CA INDEX NAME)



RN 273205-42-8 CAPLUS  
CN 3(4H)-Quinazolineacetamide, .alpha.-methyl-2-[2-(6-methyl-2-  
pyridinyl)ethenyl]-4-oxo-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.




RN 273205-43-9 CAPLUS  
CN 3(4H)-Quinazolineacetamide, .alpha.-methyl-4-oxo-2-[2-(3-  
pyridinyl)ethenyl]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.

10/ 089,166




RN 273205-44-0 CAPLUS  
CN 3(4H)-Quinazolineacetamide, 2-[2-(4-bromophenyl)ethenyl]-7-methyl-4-oxo-  
(9CI) (CA INDEX NAME)



RN 273205-45-1 CAPLUS  
CN 3(4H)-Quinazolineacetamide, .alpha.-methyl-4-oxo-2-[2-[3-(trifluoromethyl)phenyl]ethenyl]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 273205-46-2 CAPLUS  
CN 3(4H)-Quinazolineacetamide, .alpha.-methyl-8-nitro-4-oxo-2-(2-phenylethenyl)-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.


10/ 089,166



RN 273205-47-3 CAPLUS

CN 3(4H)-Quinazolineacetamide, 2-[2-(2,3-difluorophenyl)ethenyl]-.alpha.-methyl-4-oxo-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 273205-48-4 CAPLUS

CN 3(4H)-Quinazolineacetamide, .alpha.-methyl-4-oxo-2-[2-(3-phenoxyphenyl)ethenyl]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 273205-49-5 CAPLUS

CN 3(4H)-Quinazolineacetamide, N-ethyl-2-[2-(2-fluorophenyl)ethenyl]-.alpha.-[(4-hydroxyphenyl)methyl]-4-oxo-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1964:418260 CAPLUS

DOCUMENT NUMBER: 61:18260

ORIGINAL REFERENCE NO.: 61:3107d-h,3108a

TITLE: Potential anticonvulsants. Synthesis of 2,3-substituted 4-quinazolones and quinazolo-4-thiones  
 AUTHOR(S): Bhaduri, A. P.; Khanna, N. M.; Dhar, M. L.  
 CORPORATE SOURCE: Central Drug Res. Inst., Lucknow  
 SOURCE: Indian Journal of Chemistry (1964), 2(4), 159-61  
 CODEN: IJOCAP; ISSN: 0019-5103

DOCUMENT TYPE: Journal



LANGUAGE: Unavailable

GI For diagram(s), see printed CA Issue.


AB Title compds. were prepd. as potential anticonvulsants. Thus, a mixt. of 1 mole 2-methyl-4-quinazolone, 1 mole LiOH (NaOH did not work), and 1 mole appropriate phenacyl bromide (prepd. by bromination of the corresponding acetophenone) was refluxed 5 hrs. in abs. EtOH, EtOH distd., the residue extd. with C6H6, solvent distd., and the residue triturated with n-hexane to give I, which were crystd. from EtOH or C6H6-petr. ether. A mixt. 1 mole 2-methyl-3-(p-bromophenacyl)-4-quinazolone and 3-4 moles appropriate aromatic aldehyde was heated 2 hrs. at 160.degree., cooled to room temp., triturated and washed 4-5 times with ether to give I, which were crystd. from glacial HOAc. 2-Styryl- and -substituted styryl-4-quinazolones, 1 mole freshly prepd. Et2NCH2CH2Cl, and 1 mole NaOH in abs. EtOH was refluxed, the mixt. cooled and filtered, the residue extd. with CHCl3, and the solvent distd. to give I. The following I were prepd. [R, RI1, and b.p. (temps. given are bath temps.) or m.p. given]: (CH2)2Net2, CH:CHC6H4Cl-o, b10-3 210.degree.; (CH2)2Net2, CH:CHC6H3(OMe)2-3,4, b10-3 250.degree.; (CH2)2Net2, CH:CHC6H4OMe-p, b10-3 220.degree.; (CH2)2Net2, CH:CHPh, b10-3 170.degree.; (CH2)2Net2, CH:CHC6H4OMe-p, m. 149-50.degree.; CH2COC6H4Br-p, Me, m. 196-7.degree.; CH2COC6H4Br-p, CH:CHC6H4OMe-p, m. 247-8.degree.; CH2COC6H4Br-p, CH:CHPh, m. 260-1.degree.; CH2Bz, Me, m. 135-6.degree.; CH2COC6H4F-p, Me, m. 175-6.degree.; and CH2COC6H4OMe-p, Me, m. 188.degree.. A mixt. of 1 mole 2-mercapto-3-aryl-4-quinazolone and 1.05 mole P2S5 in dry xylene was refluxed 4 hrs. at 140.degree., decanted, cooled, filtered off, the solid dissolved in cold dry Me2CO or dry ether, and the soln. evapd. to give 70-80% II. The appropriate alkyl or aryl alkyl halide (1.1 mole), 1 mole 2-mercapto-3-arylquinazoline-4-thione, and 1 mole NaOH in EtOH was kept at room temp. (in the case of MeI) or refluxed 4-10 hrs. The sepd. solid was filtered off, washed with H2O, and crystd. to give II. The filtrate was evapd. to dryness, and the residue obtained triturated 3-4 times with H2O. The resulting residue contained very little of the desired product. In expts. where no solid sepd. out, EtOH was distd., the residue extd. with dry-n-hexane, the solvent removed and the concd. soln. refrigerated overnight to give II. The following II (R = Ph) were prepd. (R1 and m.p. given): H, 248-50.degree.; Me,

175-6.degree.; Et, 135-6.degree.; Pr, 79-80.degree.; CH<sub>2</sub>CH:CH<sub>2</sub>, 130-1.degree.; Bu, 74-5.degree.; Am, 63-4.degree.; CH<sub>2</sub>Ph, 158-9.degree.; CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>NO<sub>2</sub>-p, 174-5.degree.; (CH<sub>2</sub>)<sub>2</sub>Ph, 88-90.degree.; and (CH<sub>2</sub>)<sub>2</sub>NEt<sub>2</sub>, 217-18.degree.. The following II (R = o-MeOC<sub>6</sub>H<sub>4</sub>) were prepd. (data as above): H, 197-8.degree.; Me, 146-7.degree.; Et, 102-3.degree.; Pr, 82-3.degree.; Bu, 98-9.degree.; Am, 69-70.degree.; CH<sub>2</sub>CH:CH<sub>2</sub>, 100-1.degree.; CH<sub>2</sub>Ph, 115-16.degree.; CH<sub>2</sub>CO<sub>2</sub>H, 187-8.degree.; (CH<sub>2</sub>)<sub>2</sub>Ph, 103-4.degree.; and CH<sub>2</sub>COC<sub>6</sub>H<sub>4</sub>Br-p, 139-40.degree.. The following II (R = p-ClC<sub>6</sub>H<sub>4</sub>) were prepd. (data as above): H, 240-1.degree.; Me, 190-1.degree.; and Et, 147-8.degree.. The infrared spectra of II thus prepd. did not indicate the presence of a CO group, but gave a C:S peak (1360 cm.<sup>-1</sup>).

IT **95164-20-8**, 4(3H)-Quinazolinone, 2-(o-chlorostyryl)-3-[2-(diethylamino)ethyl]- **95226-84-9**, 4(3H)-Quinazolinone, 3-[2-(diethylamino)ethyl]-2-styryl- **95698-76-3**, 4(3H)-Quinazolinone, 3-[2-(diethylamino)ethyl]-2-(3,4-dimethoxystyryl)- **96369-28-7**, 4(3H)-Quinazolinone, 3-[2-(diethylamino)ethyl]-2-(p-methoxystyryl)-  
(prepn. of)  
RN 95164-20-8 CAPLUS  
CN 4(3H)-Quinazolinone, 2-(o-chlorostyryl)-3-[2-(diethylamino)ethyl]- (7CI)  
(CA INDEX NAME)





RN 95226-84-9 CAPLUS  
CN 4(3H)-Quinazolinone, 3-[2-(diethylamino)ethyl]-2-styryl- (7CI) (CA INDEX NAME)





RN 95698-76-3 CAPLUS  
CN 4(3H)-Quinazolinone, 3-[2-(diethylamino)ethyl]-2-(3,4-dimethoxystyryl)- (7CI) (CA INDEX NAME)

10/ 089,166



RN 96369-28-7 CAPLUS  
CN 4(3H)-Quinazolinone, 3-[2-(diethylamino)ethyl]-2-(p-methoxystyryl)- (7CI)  
(CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 17:54:05 ON 22 OCT 2003)

FILE 'REGISTRY' ENTERED AT 17:54:37 ON 22 OCT 2003

L1 STRUCTURE UPLOADED  
L2 29 S L1 FUL

FILE 'CAPLUS' ENTERED AT 17:55:28 ON 22 OCT 2003

L3 3 S L2

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	14.03	162.39
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.95	-1.95

STN INTERNATIONAL LOGOFF AT 17:56:03 ON 22 OCT 2003